Tag: diet pills
FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns
by Melly Alazraki on Feb.01, 2011, under Towing
In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drugs from competing pharmaceuticals have been turned back by the agency.
Continue reading FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns
FDA Rejects Orexigen’s New Diet Drug Over Heart Concerns originally appeared on DailyFinance on Tue, 01 Feb 2011 11:17:00.
Filed Under: Company News, Health Care, Stocks in the News
FDA Panel Backs Orexigen’s Diet Pill
by Melly Alazraki on Dec.07, 2010, under Towing
After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics’s Contrave. If the FDA follows the recommendation, Contrave could become the first diet drug to win approval in a decade.
Continue reading FDA Panel Backs Orexigen’s Diet Pill
FDA Panel Backs Orexigen’s Diet Pill originally appeared on DailyFinance on Tue, 07 Dec 2010 20:30:00.
Filed Under: Company News, Health Care, Stocks in the News
Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year
by Melly Alazraki on Oct.29, 2010, under Towing
Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more safety data — not another clinical trial — will lead to approval next year.
Continue reading Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year
Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year originally appeared on DailyFinance on Fri, 29 Oct 2010 11:10:00.
Filed Under: Company News, Health Care, Stocks in the News
Abbott Pulls Weight Loss Drug Meridia from the Market
by Melly Alazraki on Oct.08, 2010, under Towing
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.
Continue reading Abbott Pulls Weight Loss Drug Meridia from the Market
Abbott Pulls Weight Loss Drug Meridia from the Market originally appeared on DailyFinance on Fri, 08 Oct 2010 16:14:00.
Filed Under: Company News, Health Care, Abbott, Stocks in the News
-
You Can Reach Us At:
For All Of Your Towing and Recovery Needs.
Tele: (847) 587-6076
Fax: (847) 587-8610 Some Of Our Pics
